Atopic Dermatitis Drugs Market (Drug Type: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Atopic Dermatitis Drugs market size was estimated at USD 6.10 billion in 2021 and is expected to surpass around USD 30.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 15.7% during the forecast period 2022 to 2030.

Atopic dermatitis, also known as eczema, is a condition that affects the skin and causes itchiness, dryness, and inflammation. The condition can be chronic and tends to flare and spread sometimes. Atopic dermatitis drugs, including atopic eczema steroids, are used to treat eczema and reduce itchiness and other conditions caused by atopic dermatitis. The global atopic dermatitis drugs market size is projected to grow at a rapid pace during the forecast period owing to the rise in investment in research & development activities and novel pipeline drugs.

Report Scope of the Atopic Dermatitis Drugs Market

Increase in Incidence of Atopic Dermatitis Driving Global Market

Dermatological disorders differ across the globe based on geographic location, climatic conditions, socioeconomic status, lifestyle, age, gender, heredity, and personal habits. According to the World Health Organization (WHO), more than 900 million people were affected with skin diseases in 2017, and the five common conditions, including atopic dermatitis, accounted for around 80% of the skin disorders. High prevalence and substantial rise in incidence rate of atopic dermatitis across the globe is the key factor driving the atopic dermatitis drugs market. Atopic dermatitis affects 15% to 20% children and 1% to 3% adults across the world per year. New approvals and commercialization of novel therapeutic drugs under clinical trial studies are projected to propel the global atopic dermatitis market size during the forecast period.

Rise in Demand for Biologics Propelling Global Market

Usage of biologic drugs in dermatology has changed the treatment procedure of dermatological disorders, especially atopic dermatitis. Leading biopharmaceutical companies are investing significantly in biologic product development, merger & acquisitions, and strategic collaborations. Atopic dermatitis has shown positive response to biologics, which has improved the overall quality of life. Hence, overall demand for biologic drugs for atopic dermatitis has increased. This trend is likely to continue in the next few years. Just one biologic product has been approved for the treatment of atopic dermatitis to date. Many more are in phase II clinical trials and are likely to receive approvals in the near future.

Inhibition of Causative Inflammatory Response to Fuel Biologics Segment

In terms of drug type, the biologics segment dominated the global atopic dermatitis drugs market, with around 76% share in 2021. The trend is projected to continue during the forecast period. The segment is anticipated to be driven by the rise in prevalence of atopic dermatitis, as biologics inhibit the inflammatory response that is responsible for the development of the disease. According to the Dermatology Therapeutics Area Working Group, global prevalence rate of atopic dermatitis stands at 8% to 16% in children.

Retail Pharmacies Segment Lead Global Market

In terms of distribution channel, the global atopic dermatitis drugs market has been segmented into hospital pharmacies, retail pharmacies and online pharmacies. The retail pharmacies segment held major share of around 65% in 2021. Growth of the segment can be ascribed to the increase in purchasing power of patients and surge in the number of retail pharmacies.

Regional Outlook of Global Atopic Dermatitis Drugs Market

North America accounted for the largest share of around 46% of the global atopic dermatitis drugs market in 2021. This can be ascribed to large patient pool in the region that requires efficient and new therapies.

Europe held around 30.9% share of the global market in 2021. The market in the region is expected to grow at a faster pace from 2022 to 2030 due to the increase in focus on the development of health care infrastructure by governments and rise in demand for affordable, effective therapeutics among the significant patient population.

Asia Pacific accounted for larger market share than Latin America and Middle East & Africa in 2021. However, the market in Latin America is expected to grow at a faster pace than that in Middle East & Africa.

Analysis of Key Players in Global Atopic Dermatitis Drugs Market

The atopic dermatitis drugs market report concludes with the company profiles section, which includes key information about major players in the global atopic dermatitis drugs market. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global atopic dermatitis drugs market. Prominent players in the atopic dermatitis drugs market are Mylan N.V., Pfizer, Inc., LEO Pharma A/S, Sanofi, Novartis AG, Bausch Health, and Teva Pharmaceutical Industries Ltd.

Key Developments in Global Atopic Dermatitis Drugs Market

• In June 2022, the U.S. Food and Drug Administration (FDA) approved the first biologic Dupixent (dupilumab) for treatment of children aged six months to five years with moderate to severe dermatitis, when the disease is not adequately controlled with topical therapies
• In January 2022, Pfizer announced that the U.S. FDA had approved its CIBINQO (abrocitinib) for treating adults with moderate to severe atopic dermatitis. CIBINQO (abrocitinib) is an oral drug that contains Janus kinase 1 (JAK1) inhibitors.

Some of the prominent players in the Atopic Dermatitis Drugs Market include:

• Mylan N.V.
• Pfizer, Inc.
• LEO Pharma A/S
• Sanofi
• Novartis AG
• Bausch Health
• Teva Pharmaceutical Industries Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Atopic Dermatitis Drugs market

• Drug Type
• Corticosteroids
• PDE4 Inhibitors
• Biologics
• Skin Barrier Emollients
• CNI Immunosuppressants
• Others
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Atopic Dermatitis Drugs industry analysis from 2022 to 2030 to identify the prevailing Atopic Dermatitis Drugs industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Atopic Dermatitis Drugs industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Atopic Dermatitis Drugs industry trends, key players, market segments, application areas, and market growth strategies.